We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.
- Recent INZY Stock Price: $5.77
- Yearly Gain for INZY stock: 98.97%
- Market Cap for INZY stock: $356.36M
- P/E Ratio for INZY stock: -4.21
Will INZY's stock price go up? Is there an accurate INZY stock forecast available?
TipRanks.com reports that Inozyme Pharma, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $23.75. The target pricing ranges from a high INZY forecast of $40 down to a low forecast of $16. Inozyme Pharma, Inc. (INZY)’s last closing stock price was $5.77 which would put the average price target at 311.61% upside.
In addition, TradingView issued a rating for INZY stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on INZY stock.
Other analysts covering INZY include:
- Joseph Stringer of Needham issued a Buy rating with the price target of $23 on 1 day ago
- Tazeen Ahmad of Bank of America Securities issued a Buy rating with the price target of $16 on 5 months ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $40 on 8 months ago
If you are wondering if INZY is a good stock to buy, here are 3rd party ratings for INZY stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 31% (77 out of 252)
What is the sentiment on the street regarding Inozyme Pharma, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for INZY stock: Bullish
- Blogger Consensus for INZY stock:
- Media Buzz for INZY stock: Neutral
- Insider Signal for INZY stock: Selling
- Investor Sentiment for INZY stock: Positive
- Hedge Fund signal for INZY stock: Risk Not Mentioned
The stock market is extremely volatile, and you need to do your own research on INZY stock including scouring the social networks like INZY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for INZY stock chart >>
Summary: Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
- Recent CLSD Stock Price: $1.63
- Yearly Gain for CLSD stock: 55.24%
- Market Cap for CLSD stock: $121.80M
- P/E Ratio for CLSD stock: -2.67
Will CLSD's stock price go up? Is there an accurate CLSD stock forecast available?
TipRanks.com reports that Clearside Biomedical, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.00. The target pricing ranges from a high CLSD forecast of $6 down to a low forecast of $4. Clearside Biomedical, Inc. (CLSD)’s last closing stock price was $1.63 which would put the average price target at 206.75% upside.
In addition, TradingView issued a rating for CLSD stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CLSD stock.
Other analysts covering CLSD include:
- Andreas Argyrides of Wedbush issued a Buy rating with the price target of $4 on 22 hours ago
- Serge Belanger of Needham issued a Buy rating with the price target of $4 on 22 hours ago
- Yi Chen of H.C. Wainwright issued a Buy rating with the price target of $6 on 2 months ago
- Sean Kim PhD of JonesTrading issued a Buy rating with the price target of $6 on 2 months ago
If you are wondering if CLSD is a good stock to buy, here are 3rd party ratings for CLSD stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 31% (77 out of 252)
What is the sentiment on the street regarding Clearside Biomedical, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for CLSD stock: Bearish
- Blogger Consensus for CLSD stock:
- Media Buzz for CLSD stock: Sell
- Insider Signal for CLSD stock: Buying
- Investor Sentiment for CLSD stock: Positive
- Hedge Fund signal for CLSD stock: High Risk
The stock market is extremely volatile, and you need to do your own research on CLSD stock including scouring the social networks like CLSD StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CLSD stock chart >>
Summary: MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.
- Recent MXCT Stock Price: $4.16
- Yearly Gain for MXCT stock: 0.97%
- Market Cap for MXCT stock: $431.43M
- P/E Ratio for MXCT stock: -11.24
Will MXCT's stock price go up? Is there an accurate MXCT stock forecast available?
TipRanks.com reports that MaxCyte, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $9.50. The target pricing ranges from a high MXCT forecast of $8 down to a low forecast of $11. MaxCyte, Inc. (MXCT)’s last closing stock price was $4.16 which would put the average price target at 128.37% upside.
In addition, TradingView issued a rating for MXCT stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MXCT stock.
Other analysts covering MXCT include:
- Mark Massaro of BTIG issued a Buy rating with the price target of $8 on 22 hours ago
- Daniel Arias of Stifel Nicolaus issued a Buy rating with the price target of $11 on 2 months ago
- Jacob Johnson of Stephens issued a Buy rating with the price target of $12 on 11 months ago
If you are wondering if MXCT is a good stock to buy, here are 3rd party ratings for MXCT stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (77 out of 252)
What is the sentiment on the street regarding MaxCyte, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for MXCT stock: Bullish
- Blogger Consensus for MXCT stock:
- Media Buzz for MXCT stock: Neutral
- Insider Signal for MXCT stock: Selling
- Investor Sentiment for MXCT stock: Positive
- Hedge Fund signal for MXCT stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on MXCT stock including scouring the social networks like MXCT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MXCT stock chart >>
Summary: Cresco Labs Inc. is an integrated multistate cannabis operators principally in the United States. Its brands are designed to meet the needs of all consumer segments and comprised of brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Cresco Labs Inc. is based in CHICAGO.
- Recent CRLBF Stock Price: $1.79
- Yearly Gain for CRLBF stock: 0.00%
- Market Cap for CRLBF stock: $781.20M
- P/E Ratio for CRLBF stock: -1.63
Will CRLBF's stock price go up? Is there an accurate CRLBF stock forecast available?
TipRanks.com reports that Cresco Labs Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $4.76. The target pricing ranges from a high CRLBF forecast of $9.76 down to a low forecast of $2.4. Cresco Labs Inc. (CRLBF)’s last closing stock price was $1.79 which would put the average price target at 166.06% upside.
In addition, TradingView issued a rating for CRLBF stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on CRLBF stock.
Other analysts covering CRLBF include:
- Neal Gilmer of Haywood issued a Buy rating with the price target of $3.75 on 22 hours ago
- Derek Dley of Canaccord Genuity issued a Buy rating with the price target of $3.14 on 2 days ago
- Owen Bennett of Jefferies issued a Buy rating with the price target of $9.76 on 2 months ago
- Jesse Pytlak of Cormark Securities issued a Buy rating with the price target of $2.4 on 3 months ago
If you are wondering if CRLBF is a good stock to buy, here are 3rd party ratings for CRLBF stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Bottom 40% (152 out of 252)
What is the sentiment on the street regarding Cresco Labs Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for CRLBF stock: Bullish
- Blogger Consensus for CRLBF stock:
- Media Buzz for CRLBF stock: Neutral
- Insider Signal for CRLBF stock: -
- Investor Sentiment for CRLBF stock: Positive
- Hedge Fund signal for CRLBF stock: High Risk
The stock market is extremely volatile, and you need to do your own research on CRLBF stock including scouring the social networks like CRLBF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CRLBF stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================